GLP-1 Drugs Are Safe and Effective for Diabetic Patients with Advanced Kidney Disease, Meta-Analysis Finds | Research

The takeaway

A meta-analysis of 27,639 patients found that GLP-1 receptor agonists are safe and effective in type 2 diabetes patients with advanced or end-stage kidney disease, improving blood sugar, weight, and cardiovascular markers despite higher rates of nausea and vomiting.

27,639 patients across 8 studies
This is the largest pooled analysis to date of GLP-1 receptor agonist use in patients with advanced and end-stage kidney disease, providing the most comprehensive safety and efficacy data for this understudied population.

What the researchers found

Across 8 studies (27,639 patients), GLP-1 RAs in advanced CKD/ESKD patients showed:

- Significant reduction in cardiothoracic ratio (SMD -1.2%, 95% CI -2.0 to -0.4)

- Significant reduction in pro-BNP (SMD -335.9 pmol/L, 95% CI -438.9 to -232.8)

- Significant decrease in mean blood glucose (SMD -1.1 mg/dL, 95% CI -1.8 to -0.3)

- Significant weight loss (SMD -2.2 kg, 95% CI -2.9 to -1.5)

- No significant change in systolic blood pressure or one-year mortality

Safety: GLP-1 RAs were associated with 3.8x higher risk of nausea and 35.7x higher risk of vomiting, but no significant increase in hypoglycemia risk.

Why it matters

Advanced kidney disease patients have historically been excluded from major GLP-1 drug trials, leaving clinicians with little evidence to guide treatment decisions for this high-risk population. This meta-analysis fills a critical evidence gap, showing that GLP-1 drugs can be used safely and effectively even in patients with severely compromised kidney function — potentially expanding treatment access to millions of patients worldwide.

How the study worked

Systematic review and meta-analysis searching MEDLINE, EMBASE, and Cochrane databases through October 2023. Eight studies were included (5 trials, 3 cohort studies) involving 27,639 patients with T2DM and advanced CKD or ESKD. Risk of bias was assessed using ROBINS-I for non-randomized studies and Cochrane RoB 2 for RCTs. Protocol registered in PROSPERO (CRD 42023398452).

What this study cannot tell us

The limited number of studies (8 total) and heterogeneity between trials and cohort studies constrain the strength of conclusions. The 35.7-fold increase in vomiting risk is clinically significant, especially for dialysis patients who may already struggle with nausea. One-year mortality showed no difference, but follow-up may be too short to detect long-term survival benefits. The analysis could not determine optimal dosing for patients with varying degrees of kidney impairment.

How to read the evidence

This is a systematic review and meta-analysis — one of the highest levels of evidence — but is limited by the small number of included studies (8) and the mix of randomized trials and observational cohort studies. The heterogeneity of study designs and populations tempers the strength of pooled conclusions.

When this study was published

Published in 2024, this meta-analysis reflects the most current evidence available on GLP-1 RA use in advanced kidney disease. As more GLP-1 drugs are studied in CKD/ESKD populations, updated meta-analyses will strengthen or modify these conclusions.

The bigger picture

As GLP-1 receptor agonists become standard care for type 2 diabetes, the question of whether they can be safely used in patients with kidney failure becomes increasingly important. About 40% of diabetic patients develop some degree of kidney disease, and those with advanced CKD/ESKD have the fewest treatment options and highest cardiovascular risk. This meta-analysis provides the first pooled evidence supporting GLP-1 RA use in this population, potentially changing prescribing practices in nephrology.

Questions still open

Would dedicated large-scale RCTs of GLP-1 drugs in dialysis patients confirm the cardiovascular benefits suggested by this meta-analysis?
Can the high rate of vomiting (35.7x increase) be mitigated by slower dose titration or specific GLP-1 drug selection in kidney disease patients?
Are certain GLP-1 receptor agonists safer or more effective than others in advanced kidney disease, given differences in renal clearance?

Common questions

Why have GLP-1 drugs been understudied in kidney disease patients?

Most major GLP-1 drug trials excluded patients with advanced kidney disease (eGFR below 30 or on dialysis) due to safety concerns about altered drug metabolism and clearance. Kidneys play a role in processing some GLP-1 drugs, and severely impaired kidney function could change how the drugs work in the body. This meta-analysis helps fill that evidence gap.

Is the high vomiting rate with GLP-1 drugs in kidney patients a serious concern?

Yes — a 35.7-fold increase in vomiting is clinically significant, especially for patients on dialysis who may already experience nausea. However, the drugs did not increase dangerous hypoglycemia risk, and the cardiovascular and metabolic benefits were meaningful. Clinicians may need to start with lower doses and titrate more slowly in kidney disease patients, and patients should be closely monitored for gastrointestinal side effects.

Read the original research

Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.

Diseases (Basel, Switzerland), 12(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Krisanapan, Pajaree; Sanpawithayakul, Kanokporn; Pattharanitima, Pattharawin; Thongprayoon, Charat; Miao, Jing; Mao, Michael A; Suppadungsuk, Supawadee; Tangpanithandee, Supawit; Craici, Iasmina M; Cheungpasitporn, Wisit. (2024). Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.. Diseases (Basel, Switzerland), 12(1). https://doi.org/10.3390/diseases12010014